La chaîne d'options affiche les données clés des options sur actions de Palisade Bio à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Palisade Bio..

Palisade Bio (NASDAQ:PALI) Stock, Chaîne d'Options

Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Palisade Bio Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Paliburg Holdings Ltd

PALISADES GOLDCORP LTD by PALISADES GOLDCORP LTD.

Palisades Goldcorp Ltd

Cryptocurrency exchange and financial technology firm Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) offers a compelling mechanism to wager on digital assets without dealing with the <a href="https://www.benzinga.com/money/how-to-claim-unclaimed-bitcoin">unusual pitfalls</a> of crypto investing. These hazards include discarded hardware, forgotten passwords or even technical gremlins. Still, with Coinbase stock having virtually doubled in value this year, some skepticism may exist regarding its immediate forward viability.
Looking at the charts, Coinbase blitzed higher following the election results. Since then, however, the security has entered a sideways consolidation pattern. It's possible that it could swing higher from here. However, such a bullish development may depend on the underlying crypto ecosystem. With the <a href="https://coinmarketcap.com/charts/">total market capitalization</a> of all digital assets above $3.6 trillion, a healthy correction wouldn't be unexpected.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="826" height="475" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12153730/COIN-stock-12122024.jpg" alt="" class="wp-image-690253" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12153730/COIN-stock-12122024.jpg 826w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12153730/COIN-stock-12122024-300x173.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12153730/COIN-stock-12122024-768x442.jpg 768w" sizes="(max-width: 826px) 100vw, 826px" /></figure>
Conclusion? It's honestly a guessing game where Coinbase stock may head next. Fortunately, with an options strategy called the long iron condor, the focus is on volatility or price movement rather than the ultimate direction of the security.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42457605/exclusive-experts-share-their-top-crypto-predictions-for-2025">EXCLUSIVE: Experts Share Their Top Crypto Predictions For 2025</a>
<h2 class="wp-block-heading">Profit From Indecisiveness In COIN Stock</h2>
Paralysis by analysis represents one of the most frustrating dynamics in trading. However, if a trader is confident in a high magnitude of movement (but unclear on the asset's direction), then a long iron condor may represent an ideal solution.
An advanced options strategy, the long iron condor features four legs (or strike prices). Structurally, it helps to think of this trade as the combination of two vertical spreads; specifically, a bear put spread and a bull call spread.
Essentially, the condor features a north endzone and a south endzone. The name of the game is to get the ball across either outer strike prices to receive the full reward. A partial reward materializes when the top or bottom breakeven thresholds are breached.
By logical deduction, the long iron condor trader doesn't care where the target stock moves to, so long as it moves enough. Naturally, the worst outcome for the speculator is a decline of kinesis. Therefore, buyers of long condors anticipate a rise in <a href="https://www.benzinga.com/money/what-implied-volatility-options-trading#:~:text=Implied%20volatility%20measures%20the%20anticipated,risk%20factor%20before%20buying%20options.">implied volatility</a>.
<h2 class="wp-block-heading">Finding the Right Long Iron Condor To Trade</h2>
Given that the long iron condor rewards heightened volatility, it makes sense for traders to seek "narrow" strike price ranges. That way, there's less distance for the ball to reach either endzone. However, narrow long iron condors typically feature significant positional risk (a large cash outlay) in exchange for the reduced probabilistic risk (likelihood that the trade will be successful). Also, highly probable trades usually feature miniscule payouts.
On the other hand, "wide" long iron condors tempt traders with the biggest payouts and low positional risk. However, the probabilistic risk tends to be so great that such transactions should be viewed extremely carefully, if not skeptically.
Subsequently, finding the right long iron condor involves a balancing act. The ideal condor will feature a reasonable probability that the ball can reach either endzone. This balance is important because the trader is paying a premium to attack both profitability targets. If the trader had a strong directional bias, it would make sense to just pay for one vertical spread — either a bear put or a bull call.
Based on the week-to-week mobility of COIN stock, the 287.50P &#x7C; 295.00P &#x7C;&#x7C; 310.00C &#x7C; 317.50C condor for the options chain expiring Dec. 20, 2024, may make sense. This is how the trade breaks down:
<ul>
<li>Sell the $287.50 put.</li>
<li>Buy the $295 put.</li>
<li>Buy the $310 call.</li>
<li>Sell the $317.50 call.</li>
</ul>
With this setup, there's a reasonable chance — given COIN stock's high mobility — to reach either profitability target. Further, the payout, while not particularly great at 33% at the time of writing, still affords the trader a mechanism to win if COIN marches higher or if an unexpected headwind temporarily derails the bullish narrative.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/24/12/42470479/financial-advisor-calls-stocks-dinosaur-bones-but-likes-some-etfs">&#8216;Crypto Hippie&#8217; Financial Advisor Calls Stocks &#8216;Dinosaur Bones&#8217; — But Likes Some ETFs</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Technicals

Options

Trading Ideas

COIN

Options Corner: Turn Coinbase's Volatility Into Opportunity With Long Iron Condors

News

Dividends

Edison International Raises Common Stock Dividend From $0.78 To $0.8275/Share

Merger and acquisitions activity peaked in the United States in 2021, but after SPACs got shellacked and the Biden administration took a harsher view of large-scale mergers, deals became fewer and further between.
This trend is expected to reverse in 2025 as the Federal Reserve lowers interest rates and a more M/A-friendly Federal Trade Commission (FTC) enters the fold. Analysts at Goldman Sachs expect many <a href="https://finance.yahoo.com/news/goldman-sachs-sees-more-larger-162800585.html">larger-scale deals</a> to be explored in the next 12 months, and one may already be underway as Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLDZ#NASDAQ">MLDZ</a>) is again considering purchasing chocolate conglomerate Hershey Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>).
Today, we'll explore five more stocks that could be M/A targets in 2025.
<h2 class="wp-block-heading">How We Made Our Picks</h2>
Fitch Ratings has identified <a href="https://www.fitchratings.com/research/corporate-finance/us-corporate-m-a-could-accelerate-in-2025-credit-implications-mixed-02-12-2024">several sectors</a> with ample dry powder and legroom for acquisitions, such as homebuilding and construction, aerospace, gaming and leisure, healthcare, banking, and (of course) tech. We looked for companies in these industries and narrowed down our selections based on growth potential, brand recognition, financial position, and number of potential suitors. These are primarily mid-size firms with market caps between $5 and $12 billion.
<h3 class="wp-block-heading">Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>)</h3>
If you're annoyed waiting in long lines at Starbucks or Dunkin&#8217; for your morning coffee, you aren't alone. Even with mobile orders and online promos, drive-thru lines are a constant pressure point for big chains, and as coffee prices continue to rise, customers might consider eschewing the line altogether.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="304" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/Bros-1024x304.png" alt="" class="wp-image-690339" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/Bros-1024x304.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/Bros-300x89.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/Bros-768x228.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/Bros.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Artisan coffee chains like Dutch Bros might be a way for bigger companies to gain a competitive edge without sacrificing quality. BROS is a fast-growing coffee chain with over 900 stores in the United States, mainly in the Western part of the country, that prides itself on quick drive-thru experiences and attentive service. While 900 stores might seem quaint to giants like Starbucks, this is impressive growth from the 135 stores in operation in 2009, and the company also sells its name-brand varieties online. Dutch Bros revenue growth has continued its steady ascent, and gross profits have more than doubled since 2020. BROS is a takeover target thanks to these expanding profits, minimal debt load, strong brand recognition, and potentially untapped markets in the coffee-crazed northeastern United States.
<h3 class="wp-block-heading">Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
Walgreens has long been a takeover target, but realistic dealmaking scenarios have failed to materialize, and the stock has been stuck in a multi-year decline. While a public acquisition has eluded WBA, 2025 could be the year the company returns to private markets.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="304" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/WBA-1024x304.png" alt="" class="wp-image-690340" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/WBA-1024x304.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/WBA-300x89.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/WBA-768x228.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163047/WBA.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
On December 10, news broke that Sycamore Partners was <a href="https://www.benzinga.com/24/12/42421855/walgreens-stock-jumps-on-report-of-potential-private-equity-sale-what-you-need-to-know">exploring an acquisition</a> of Walgreens, who intend to take the company private and potentially split up its divisions. WBA stock has plummeted from a $100 billion market cap in 2015 to just $8.5 billion at the end of 2024, making a private market acquisition much more feasible.
<a href="https://bzresearch.myclickfunnels.com/earnings-gaps-masterclass-registration/?utm_source=RD-1213">Last Chance Before 2025 Earnings Season</a>
<h3 class="wp-block-heading">Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)</h3>
Roku's stock chart will forever be distorted by the COVID-19 pandemic and meme stock craze, which saw its price jump from $100 to $500 in less than a year. When rates began rising in early 2022, ROKU was decimated and has traded under $100 per share for the better part of the last two years. But Netflix and Disney+ have shown that streaming services are the new way Americans watch TV, and Roku provides hardware and software to bring these services into living rooms.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="299" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ROKU-1024x299.png" alt="" class="wp-image-690341" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ROKU-1024x299.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ROKU-300x88.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ROKU-768x224.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ROKU.png 1300w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
ROKU made a record $1.5 billion in gross profits in 2023 thanks to more customers ditching cable for streaming services requiring Roku's products, such as smart TVs, streaming sticks, and the all-new Roku Ultra, the company's fastest and highest-quality device. ROKU's market cap is just under $12 billion, which is couch cushion cash for companies like Disney, Netflix, or Apple that could benefit from adding a hardware supplier that can entice potential customers to sign up for their services (and steer them from the competition).
<h3 class="wp-block-heading">Zoom Video Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>)</h3>
Another company with a rollercoaster stock chart is Zoom, the video conferencing service that kept people connected during the height of the COVID-19 pandemic. Zoom found itself in the right place at the right time, and its stock exploded from $76 in January 2020 to nearly $500 by the start of November. But by August 2022, the stock had given up all its COVID gains and settled back under $100.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="300" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ZM-1024x300.png" alt="" class="wp-image-690342" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ZM-1024x300.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ZM-300x88.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ZM-768x225.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163048/ZM.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
ZM shares have traded under the $100 mark for most of the last two years, but the previous three months have shown the stock shaking off the cobwebs. In October, ZM's 50-day moving average made a bullish cross over the 200-day MA, and there's optimism that Zoom's infrastructure, brand recognition, and return to positive sales growth will make it a desirable acquisition in 2025. With a $26 billion market cap, Zoom needs a buyer with deep pockets like Google, Microsoft, or Apple, but the company has plenty of positive free cash flow and a sturdy balance sheet.
<h3 class="wp-block-heading">SPDR Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>)</h3>
Now, no one is actually looking to acquire a banking ETF. However, the small and mid-size bank sector is ripe for consolidation, and the performance of this index shows how much optimism has flooded the industry since Donald Trump's election night victory. In 2023, the number of FDIC-insured commercial banks <a href="https://www.statista.com/statistics/184536/number-of-fdic-insured-us-commercial-bank-institutions/">grew to 4,470</a>, the first expansion in more than two decades (over 8,000 banks were insured in 2000). Many market analysts believe this to be a one-time blip and expect consolidation to resume under new FTC leadership.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="300" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163103/KRE-1024x300.png" alt="" class="wp-image-690343" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163103/KRE-1024x300.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163103/KRE-300x88.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163103/KRE-768x225.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12163103/KRE.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The S&amp;P Regional Banking ETF got a massive boost on the Wednesday following the presidential election as a deregulation agenda paves the way for bank mergers and acquisitions. KRE is a relatively small fund with only $5.7 billion in assets under management, but it holds a diverse range of regional banking stocks. Over 140 banks and financial services firms fill the index, ranging from large caps like Truist Financial ($60 billion market cap) to niche local banks like Atlantic Union Bancshares (under $4 billion market cap). Selecting which of the more than 4,000 banks will be acquired is a monumental task; buying this small ETF is a way to take advantage of the overall M/A trend.
Join two veteran traders December 15th for their complete system: Find perfect entries, manage risk, and catch potential +1,452% winners others miss. <a href="https://bzresearch.myclickfunnels.com/earnings-gaps-masterclass-registration/?utm_source=WebRD-1213">SAVE MY SPOT</a>
Photo via Shutterstock

Opinion

BROS

MLDZ

ROKU

5 Merger and Acquisition Targets to Buy Before Trump Takes Over

Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) reported its fourth-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/news/earnings/24/09/40741225/broadcom-q3-earnings-revenue-beat-eps-beat-continued-strength-in-ai-solutions-and-vmware-2024-ai-gu">figures from the quarter.&nbsp;</a>
The Details: Broadcom reported quarterly earnings of $1.42 per share, which beat the analyst consensus estimate of $1.38. Quarterly revenue came in at $14.05 billion, which slightly missed the consensus estimate of $14.09 billion and is an increase over sales of $9.295 billion from the same period last year.
The company reported non-GAAP net income of $6.965 billion for the fourth quarter and cash from operations of $5.604 billion for the fourth quarter, less capital expenditures of $122 million, resulting in $5.482 billion of free cash flow. 
&#8220;Broadcom&#8217;s fiscal year 2024 revenue grew 44% year-over-year to a record $51.6 billion, as infrastructure software revenue grew to $21.5 billion, on the successful integration of VMware,&#8221; said Hock Tan, CEO of Broadcom Inc.
&#8220;Semiconductor revenue was a record $30.1 billion driven by AI revenue of $12.2 billion. AI revenue which grew 220 percent year-on-year was driven by our leading AI XPUs and Ethernet networking portfolio,&#8221; Tan added. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Broadcom Q4 2024 Earnings Call &#x7C; $AVGO" width="500" height="281" src="https://www.youtube.com/embed/CFJjPNvHdLk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42440681/markets-have-the-green-light-to-rally-after-novembers-yawner-inflation-report-experts-say">&#8216;Markets Have The Green Light To Rally&#8217; After November&#8217;s &#8216;Yawner&#8217; Inflation Report, Experts Say</a>
Outlook:&nbsp;Broadcom sees first-quarter revenue of approximately $14.6 billion, versus the $14.612 billion estimate. The company also issued adjusted EBITDA guidance of approximately 66 percent of projected revenue for the first quarter. 
AVGO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Broadcom shares are up 5.27% after-hours at $190.54 at the time of publication Thursday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42374462/robinhood-markets-grows-into-best-in-class-brokerage-analyst-says">Robinhood Markets Grows Into &#8216;Best-In-Class&#8217; Brokerage, Analyst Says</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

After-Hours Center

Movers

Tech

AVGO

Broadcom Reports Mixed Q4 Results: EPS Beat, Revenues Miss, Q1 Guidance In Line With Estimates

W. P. Carey Increases Quarterly Dividend From $0.875 To $0.880 Per Share

Previously announced in April 2024, the original repurchase authorization encompassed 507,707 shares of common stock, representing approximately 10% of the then outstanding shares.&nbsp;
To date, the Company has repurchased 397,008 shares at an average price of $9.15 per share. The additional repurchase authorization represents approximately 5% of pro forma outstanding shares assuming the repurchase of the remaining shares subject to the original authorization.

Buybacks

FSEA

First Seacoast Bancorp Plans Additional Share Repurchases, Up To An Additional 228,858 Shares Of Common Stock, Under Its Ongoing Program

Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.
Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement.

Global

BNOX

Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 4.24% on an annualized basis producing an average annual return of 15.83%. Currently, Zoetis has a market capitalization of $80.69 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $437.80 today based on a price of $178.84 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734039012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Seth Rogen's Houseplant is at it again. The "Freaks and Geeks" and "Pineapple Express" actor and filmmaker's cannabis lifestyle brand launched a THC-infused, flavored <a href="https://www.benzinga.com/topic/cannabis-beverages">sparkling water on Thursday</a>.
Since its U.S. debut in March 2021, Houseplant — co-founded by Rogen, Evan Goldberg and Michael Mohr — has been a leader in destigmatizing cannabis culture with its tasteful and thoughtfully designed lifestyle and home goods. 
Each of Houseplant&#8217;s products, <a href="https://www.benzinga.com/markets/cannabis/23/01/30651350/smoke-weed-with-seth-rogen-make-a-ceramic-ashtray-with-him-spend-the-night-airbnb-is-hosting">including ceramic ashtrays and other cannabis-themed artwork</a>, has a story behind it that&#8217;s been brought to life through thoughtful planning and lots of creativity. The same goes now for its THC-infused beverages.
&#8220;At Houseplant, our approach has always been to create the products we wish existed — and to do so with the highest standards,&#8221; <a href="https://www.prnewswire.com/news-releases/houseplant-launches-ready-to-drink-thc-infused-sparkling-waters-302329738.html">said</a> Mohr, Houseplant CEO in a press release. &#8220;It has been thrilling to innovate with THC beverages, creating a drink that&#8217;s both accessible in strength and convenient, in a familiar, smoke-free format.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">Daily Cannabis Consumption Outpaces Daily Alcohol Use In The US For The First Time, New Study Shows</a>
<h2 class="wp-block-heading">Not Everyone Wants To Smoke</h2>
&#8220;Not every situation is right for smoking, and not everyone wants to smoke,&#8221; said Rogen. &#8220;Houseplant beverages offer an approachable dose that&#8217;s perfect for those trying THC for the first time and for regular consumers like me who will love having a delicious, low-calorie, drinkable option. It&#8217;s sparkling water with THC in it &#8211; everybody loves a Houseplant.&#8221;
Mohr added that the launch was a natural step in Houseplant's evolution. &#8220;We are excited to be a part of this THC renaissance and look forward to bringing more products to market that millions of people are proud to own and consume.&#8221;
<h2 class="wp-block-heading">Tribute To Pineapple Express?</h2>
&#8220;Pineapple Express,&#8221; for those who may have missed it in 2008, is a hilarious buddy stoner action flick written by Seth Rogen who starred in it along with Evan Golberg and James Franco. 
The Food &amp; Wine Guide <a href="https://www.foodandwine.com/seth-rogen-houseplant-thc-infused-sparkling-water-8760145">noted</a> that after taste-testing every sparkling water they could find, the Houseplant threesome (Rogen, Goldberg, Mohr) landed on four sugar-free flavors: pineapple, citrus, black cherry and blackberry.
"It all starts with making something we would love to own or consume ourselves," said Mohr. "Black cherry is a classic flavor we all grew up drinking; citrus is a staple in all our fridges; blackberry is a bit more rare, but we figured out how to put our own spin on it and managed to make it incredibly delicious; and then pineapple — well, there's a little wink in there to Pineapple Express."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42466804/biden-commutes-1500-sentences-grants-39-pardons-pot-prisoners-included-marks-single-day-record">Biden Commutes 1,500 Sentences, Grants 39 Pardons — Pot Prisoners Included — Marks Single-Day Record</a></li>
</ul>
Photo courtesy of Houseplant

Cannabis

Entertainment

Retail Sales

Seth Rogen Launches Cannabis-Infused Sparkling Water Because 'Not Everyone Wants To Smoke'

LDTC

LeddarTech Received First Installment Of TI Pre-Paid Royalty Fee

As previously disclosed, due to EVERFI performing below expectations, Blackbaud is considering a range of alternatives for EVERFI, one of which includes a potential divestiture of the business. The impairment charge was determined to be necessary as part of this process.
&nbsp;
 &nbsp;

BLKB

Blackbaud Expects Material Pre-tax Noncash Impairment Charge, Which May Be Up To $415M, Is Required For Its EVERFI Asset Group And Will Be Recorded During Q4 Of 2024

The Board of Directors of SEI Investments Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) on Dec. 12, 2024 declared a regular semi-annual dividend of $0.49 per share, an increase from the prior semi-annual dividend of $0.46. The cash dividend will be payable to shareholders of record on Dec. 27, 2024, with a payment date of Jan. 8, 2025.

SEIC

SEI Increases Semi-Annual Dividend From $0.46 To $0.49 Per Share

WIIM

GTIM

Good Times Restaurants shares are trading higher after the company reported a year-over-year increase in Q4 financial results and announced a $2 million expansion for its share repurchase program.

Biotech

General

RPTX

Repare Therapeutics Announces Pretreated Patients On Lunresertib And Camonsertib Combination Achieved 25.9% Overall Response Rate In Endometrial Cancer And 37.5% In Platinum-Resistant Ovarian Cancer

Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care
Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025
Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results

Repare Therapeutics Reported Results Of Lunresertib And Camonsertib Combination From MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Redwood Trust Increases Common Dividend From $0.17 To $0.18 Per Share

Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.79 by 0.79 percent. The company reported quarterly sales of $62.151 billion which beat the analyst consensus estimate of $62.083 billion by 0.11 percent. This is a 7.53 percent increase over sales of $57.799 billion the same period last year.

COST

CORRECTION: Costco Wholesale Q1 2025 Adj. EPS $3.82 Beats $3.79 Estimate, Sales $62.151B Beat $62.083B Estimate

Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) reported its Q4 earnings results on Thursday, December 12, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Quanex Building Prods beat estimated earnings by 9.0%, reporting an EPS of $0.61 versus an estimate of $0.56.
Revenue was up $196.67 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.03 in the previous quarter, leading to a 22.0% increase share price change the next day.
Here's a look at Quanex Building Prods's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.54</td>
<td>0.11</td>
<td>0.70</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.73</td>
<td>0.66</td>
<td>0.18</td>
<td>0.95</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>278.46M</td>
<td>268.03M</td>
<td>231.43M</td>
<td>291.01M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>280.35M</td>
<td>266.20M</td>
<td>239.16M</td>
<td>295.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Quanex Building Prods <a href="https://www.benzinga.com/quote/NX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Quanex Building Prods Q4 Earnings

The Q1 dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 21, 2025.

Zoetis Boosts Quarterly Dividend By 16% From $0.432 To $0.50 Per Share

Arcosa Renews $50M Share Repurchase Authorization

Warning: PALI is at high risk of performing badly

Palisade Bio GAAP EPS of -$2.32 beats by $1.03

"I am extremely proud of the clinical progress our team has made over this past quarter. The initiation of our Phase 1 clinical trial and patient e...

Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year

As of September 30, 2024, the Company had cash and cash equivalents of $8.0 million. The Company believes it has sufficient cash to fund its curren...

Palisade Bio expects cash to fund operations through 1Q25

Maxim lowered the firm's price target on Palisade Bio (PALI) to $8 from $22.50 and keeps a Buy rating on the shares. The company reported Q3 result...

Palisade Bio price target lowered to $8 from $22.50 at Maxim

Brookline initiated coverage of Palisade Bio (PALI) with a Buy rating and $38 price target Palisade Bio is advancing novel therapeutics for patient...

Palisade Bio initiated with a Buy at Brookline

Palisade Bio (PALI) announced preliminary results from its first three single ascending dose, SAD, cohorts in its ongoing Phase 1 human clinical st...

Palisade Bio announces preliminary results from Phase 1 study of PALI-2108

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (EW – Research Report), Evole...

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)

PALI

Press Releases

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Power Nickel Inc. (TSXV: PNPN) New 52-Week High's Amid Breakthrough Discoveries and Strategic Growth see more stocks inside….

BURU

KAVL

LAES

PNPNF

TSXV:PNPN

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

Molecular Templates

NuCana

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Palisade Bio

Palisade Bio (PALI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL